Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00509006 | Breast | Precancer | leukocyte migration | 47/1080 | 369/18723 | 2.82e-07 | 1.39e-05 | 47 |
GO:00305956 | Breast | Precancer | leukocyte chemotaxis | 34/1080 | 230/18723 | 4.16e-07 | 1.89e-05 | 34 |
GO:00603266 | Breast | Precancer | cell chemotaxis | 41/1080 | 310/18723 | 5.99e-07 | 2.55e-05 | 41 |
GO:00507293 | Breast | Precancer | positive regulation of inflammatory response | 23/1080 | 142/18723 | 6.51e-06 | 1.81e-04 | 23 |
GO:0050727 | Breast | Precancer | regulation of inflammatory response | 44/1080 | 386/18723 | 1.26e-05 | 3.22e-04 | 44 |
GO:00321034 | Breast | Precancer | positive regulation of response to external stimulus | 46/1080 | 427/18723 | 3.41e-05 | 7.40e-04 | 46 |
GO:00313493 | Breast | Precancer | positive regulation of defense response | 33/1080 | 278/18723 | 6.79e-05 | 1.36e-03 | 33 |
GO:00310995 | Breast | Precancer | regeneration | 25/1080 | 198/18723 | 1.91e-04 | 3.06e-03 | 25 |
GO:0045766 | Breast | Precancer | positive regulation of angiogenesis | 23/1080 | 181/18723 | 3.09e-04 | 4.43e-03 | 23 |
GO:1904018 | Breast | Precancer | positive regulation of vasculature development | 23/1080 | 181/18723 | 3.09e-04 | 4.43e-03 | 23 |
GO:0045765 | Breast | Precancer | regulation of angiogenesis | 35/1080 | 342/18723 | 7.35e-04 | 8.80e-03 | 35 |
GO:0070265 | Breast | Precancer | necrotic cell death | 11/1080 | 62/18723 | 7.54e-04 | 9.01e-03 | 11 |
GO:1901342 | Breast | Precancer | regulation of vasculature development | 35/1080 | 348/18723 | 1.00e-03 | 1.12e-02 | 35 |
GO:00622083 | Breast | Precancer | positive regulation of pattern recognition receptor signaling pathway | 8/1080 | 44/18723 | 3.31e-03 | 2.78e-02 | 8 |
GO:0034123 | Breast | Precancer | positive regulation of toll-like receptor signaling pathway | 6/1080 | 28/18723 | 4.58e-03 | 3.53e-02 | 6 |
GO:005090011 | Breast | IDC | leukocyte migration | 54/1434 | 369/18723 | 3.10e-06 | 1.15e-04 | 54 |
GO:003059511 | Breast | IDC | leukocyte chemotaxis | 38/1434 | 230/18723 | 5.36e-06 | 1.76e-04 | 38 |
GO:006032611 | Breast | IDC | cell chemotaxis | 46/1434 | 310/18723 | 1.13e-05 | 3.08e-04 | 46 |
GO:003109912 | Breast | IDC | regeneration | 31/1434 | 198/18723 | 1.08e-04 | 2.03e-03 | 31 |
GO:00313491 | Breast | IDC | positive regulation of defense response | 39/1434 | 278/18723 | 1.74e-04 | 2.95e-03 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NIN | SNV | Missense_Mutation | novel | c.6193G>T | p.Val2065Leu | p.V2065L | Q8N4C6 | protein_coding | tolerated(1) | probably_damaging(0.996) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NIN | SNV | Missense_Mutation | novel | c.4571C>A | p.Ser1524Tyr | p.S1524Y | Q8N4C6 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NIN | SNV | Missense_Mutation | rs147387454 | c.6061N>A | p.Glu2021Lys | p.E2021K | Q8N4C6 | protein_coding | tolerated(0.08) | possibly_damaging(0.458) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
NIN | SNV | Missense_Mutation | | c.65N>T | p.Thr22Met | p.T22M | Q8N4C6 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AJ-A3OK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
NIN | SNV | Missense_Mutation | | c.5300A>G | p.Lys1767Arg | p.K1767R | Q8N4C6 | protein_coding | tolerated(0.09) | probably_damaging(0.991) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NIN | SNV | Missense_Mutation | rs185029649 | c.3570G>T | p.Arg1190Ser | p.R1190S | Q8N4C6 | protein_coding | tolerated(0.08) | benign(0.12) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NIN | SNV | Missense_Mutation | | c.1981N>C | p.Glu661Gln | p.E661Q | Q8N4C6 | protein_coding | deleterious(0.04) | possibly_damaging(0.81) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
NIN | SNV | Missense_Mutation | | c.5817N>G | p.Ile1939Met | p.I1939M | Q8N4C6 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NIN | SNV | Missense_Mutation | | c.5032N>T | p.Leu1678Phe | p.L1678F | Q8N4C6 | protein_coding | tolerated(0.12) | benign(0.189) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NIN | SNV | Missense_Mutation | | c.4549N>A | p.Glu1517Lys | p.E1517K | Q8N4C6 | protein_coding | tolerated(0.09) | probably_damaging(0.994) | TCGA-AP-A0LF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |